IP Verse

Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension

Patent No. EP3897646 (titled "Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension") was filed by Actelion Pharmaceuticals on Dec 20, 2019. The application was issued on May 22, 2024.

Patent Summary

A combination therapy for pulmonary arterial hypertension (PAH) that targets patients with mild to moderate disease. The treatment involves administering macitentan at a high dose of 60-90 mg/day, with a preferred regimen of 75 mg/day. This combination therapy combines macitentan with phosphodiesterase type 5 inhibitors (PDE5is) and prostacyclin analogues, offering improved disease control and potential long-term benefits over traditional treatments.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKFeb 21, 2025ELKINGTON AND FIFE
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETIFeb 21, 2025SONNENHAUSER
SANDOZFeb 7, 2025ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3897646

ACTELION PHARMACEUTICALS
Application Number
EP19832954A
Filing Date
Dec 20, 2019
Status
Granted And Under Opposition
Apr 19, 2024
Publication Date
May 22, 2024
External Links
Slate, Register , Google Patents